Connect Biopharma Holdings (CNTB) Total Non-Current Liabilities (2020 - 2026)

Connect Biopharma Holdings has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $16.5 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 46.56% year-over-year to $16.5 million; the TTM figure through Jun 2026 stood at $16.5 million (up 46.56% YoY), while the FY2025 annual figure was $14.0 million, up 64.75% from the prior year.
• Total Non-Current Liabilities came in at $16.5 million for Q2 2026 at Connect Biopharma Holdings, down from $17.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $17.3 million in Q1 2026 to a low of $467000.0 in Q2 2024.
• Average Total Non-Current Liabilities over 5 years is $7.7 million, with a median of $8.8 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities tumbled 53.94% in 2023 and jumped 2311.35% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $877791.3 in 2022, then plunged by 33.36% to $585000.0 in 2023, then jumped by 1350.6% to $8.5 million in 2024, then jumped by 64.75% to $14.0 million in 2025, then increased by 18.05% to $16.5 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $16.5 million in Q2 2026, $17.3 million in Q1 2026, and $14.0 million in Q4 2025.